Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director | September 03, 2026 | September 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 328,436 |
Ending reported balance
After 2026-09-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-03 · Sale · Disposed 7,012 · Balance 341,424 F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-03 · Sale · Disposed 6,814 · Balance 334,610 F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-03 · Sale · Disposed 6,174 · Balance 328,436 F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $60.435 to $61.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F2: This transaction was executed in multiple trades at prices ranging from $61.435 to $62.35. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $62.50 to $62.86. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $181.47 | $199,619.64 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,316 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $180.98 to $181.93. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 960 | $180.33 | $173,114.98 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,416 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $179.98 to $180.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,140 | $179.53 | $204,668.87 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,376 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $178.98 to $179.955. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 16:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $178.48 | $196,323.49 |
DisclosureSEC source: 0001209191-21-049653 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,516 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $177.98 to $178.955. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 16:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $171.44 | $102,864.48 |
DisclosureSEC source: 0001209191-21-047362 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $171.34 to $171.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 16:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,190 | $170.83 | $374,117.70 |
DisclosureSEC source: 0001209191-21-047362 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,216 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $170.29 to $171.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 16:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,710 | $169.75 | $290,263.95 |
DisclosureSEC source: 0001209191-21-047362 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,406 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $169.24 to $170.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 16, 2021 Filed Jul 20, 2021 16:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $168.57 | $84,282.50 |
DisclosureSEC source: 0001209191-21-047362 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,116 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $168.075 to $169.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $196.00 | $39,200.00 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $195.82 to $196.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $194.29 | $97,143.45 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,816 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $194.03 to $194.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $193.51 | $135,454.48 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,316 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $193.02 to $193.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $191.97 | $134,381.38 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.46 to $192.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,300 | $190.87 | $248,126.97 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,716 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.40 to $191.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:30 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,600 | $189.94 | $303,908.80 |
DisclosureSEC source: 0001209191-21-045480 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.385 to $190.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $203.42 | $20,342.00 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 10 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,616 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $202.18 | $60,652.89 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 9 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,716 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $201.825 to $202.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $201.03 | $201,026.20 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 8 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $200.74 to $201.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $200.23 | $340,392.53 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,016 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $199.725 to $200.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $199.30 | $119,581.26 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,716 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $198.72 to $199.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $197.75 | $98,874.50 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,316 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $197.48 to $198.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $196.75 | $78,698.52 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,816 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $196.36 to $197.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $195.30 | $39,059.00 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,216 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $194.99 to $195.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $191.97 | $19,197.00 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,416 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 17:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $190.97 | $19,097.00 |
DisclosureSEC source: 0001209191-21-042115 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,516 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $193.51 | $0.00 |
DisclosureSEC source: 0001209191-21-040695 · doc4.xml · derivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563 Underlying: Class A Common Stock · 1,563 shares Expires 2031-06-11 F2 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one-twelfth of the shares on July 11, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040695 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,616 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-fourth of the RSUs, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, shall vest on August 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $179.78 | $53,933.01 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 8 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $179.38 to $180.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $178.21 | $53,463.99 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,291 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $177.745 to $178.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $176.72 | $17,672.00 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,400 | $175.77 | $421,838.64 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $175.44 to $176.17. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $174.80 | $262,200.00 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $174.27 to $175.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $173.72 | $104,232.00 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,591 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $173.16 to $174.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 703 | $172.56 | $121,307.08 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $172.09 to $173.025. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 18:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,597 | $171.58 | $274,017.89 |
DisclosureSEC source: 0001209191-21-037904 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,894 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $171.04 to $172.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $144.49 | $86,691.00 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $144.10 to $144.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $143.44 | $143,439.50 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $143.10 to $144.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $142.48 | $142,482.40 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $142.10 to $143.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,800 | $141.36 | $254,451.96 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $141.10 to $141.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,600 | $140.34 | $364,882.18 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $140.00 to $140.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 17, 2021 Filed May 19, 2021 18:18 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $139.59 | $69,793.25 |
DisclosureSEC source: 0001209191-21-034132 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $139.00 to $139.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $198.09 | $19,809.00 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,991 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $194.90 | $19,490.00 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,091 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $193.84 | $58,152.00 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $193.38 to $194.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,200 | $192.54 | $423,582.72 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 4 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $192.26 to $193.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,880 | $191.83 | $552,461.76 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 3 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,691 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $191.19 to $192.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,320 | $190.53 | $251,504.35 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 2 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,571 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $190.13 to $191.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $189.25 | $113,550.72 |
DisclosureSEC source: 0001209191-21-030399 · doc4.xml · nonDerivative · entry 1 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $189.09 to $189.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $195.74 | $58,722.99 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 7 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,491 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $195.50 to $196.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,393 | $194.83 | $271,393.73 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 6 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,791 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $194.40 to $195.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 17:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,600 | $193.86 | $310,172.00 |
DisclosureSEC source: 0001209191-21-027322 · doc4.xml · nonDerivative · entry 5 STUELPNAGEL JOHN R · CIK 0001189140 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,184 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $193.40 to $194.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.